Companies › Sanaria
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PfSPZ-LARC2 Vaccine Double deletion of MEI2 and LINUP genes in Plasmodium falciparum NF54 sporozoites - arrest | LINUP, MEI2 | Phase 2 | Malaria (Plasmodium Falciparum); Malaria Falciparum | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07385287 | PfSPZ-LARC2 Vaccine | Phase 2 | Malaria (Plasmodium Falciparum) | Infectious disease | Feb 2027 |
| NCT06862453 | PfSPZ-LARC2 Vaccine | Phase 1 | Malaria Falciparum | Infectious disease | Aug 2027 |
| NCT07675785 | PfSPZ-LARC2 Vaccine | Phase 2 | Malaria (Plasmodium Falciparum) | Infectious disease | Jul 2028 |
Eveliqure Biotechnologies CastleVax Medicago Brii Biosciences SIGA Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.